Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2026 08:00 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and...
March 11, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...
March 06, 2026 16:10 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
March 05, 2026 13:00 ET | Source: Exousia Pro, Inc.

Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions

(OTCPK: MAJI) announces several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.
March 02, 2026 08:00 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla.,...
March 01, 2026 21:03 ET | Source: InnoCare Pharma

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

InnoCare’s next-generation TRK inhibitor Zurletrectinib receives priority review for the treatment of pediatric patients with solid tumors in China.
February 25, 2026 22:56 ET | Source: InnoCare Pharma

InnoCare Announces Key Developments of Critical Clinical Studies

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.
February 25, 2026 17:12 ET | Source: kneat.com, inc.

Kneat Achieves Record Revenue for Fourth Quarter and Full Year 2025

kneat.com reports record fourth-quarter and full year 2025 results with highest-ever new customer wins in 2025.
February 24, 2026 15:42 ET | Source: Transpire Bio

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic...
February 23, 2026 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...